A Translational View of the Molecular Pathogenesis of Lung Cancer
- 1 April 2007
- journal article
- review article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 2 (4), 327-343
- https://doi.org/10.1097/01.jto.0000263718.69320.4c
Abstract
No abstract availableKeywords
This publication has 155 references indexed in Scilit:
- Differential disruption of cell cycle pathways in small cell and non-small cell lung cancerBritish Journal of Cancer, 2006
- Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancersInternational Journal of Cancer, 2006
- Oncogenic pathway signatures in human cancers as a guide to targeted therapiesNature, 2005
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- Live or let die: the cell's response to p53Nature Reviews Cancer, 2002
- Mutations of the BRAF gene in human cancerNature, 2002
- The Hallmarks of CancerCell, 2000